Form 483

Contract Pharmaceuticals Limited Canada Form 483, 2018-03-29

FDA issued a Form 483 to Contract Pharmaceuticals Limited Canada on 2018-03-29 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Contract Pharmaceuticals Limited Canada · Mississauga, Canada · Issued March 29, 2018

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

29 Mar 2018
21 CFR 211.142

Written warehousing procedures established/followed

Cited by Cheryl A Clausen

29 Mar 2018
21 CFR 211.150(b)

Distribution Recall System

Cited by Cheryl A Clausen

29 Mar 2018
21 CFR 211.170(b)

Annual visual exams of drug products

Cited by Cheryl A Clausen

29 Mar 2018
21 CFR 211.198(a)

Complaint Handling Procedure

Cited by Cheryl A Clausen

29 Mar 2018
21 CFR 211.22(a)

Approve or reject components, products

Cited by Cheryl A Clausen

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.142Cited across public-safe Form 483 observations1x
21 CFR 211.150(b)Cited across public-safe Form 483 observations1x
21 CFR 211.170(b)Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x
21 CFR 211.82(a)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere